Fundamentos Teóricos: Antidiabéticos | Endocrinología | Dr. Luis Villar
Overview of Diabetes Pharmacotherapy
Introduction to Diabetes Medications
- The discussion begins with an overview of diabetes medications, emphasizing the importance of understanding their characteristics, adverse effects, and indications.
- Acknowledges the significant increase in new diabetes drugs over the past 20 years, highlighting that diabetes was declared a global pandemic in 2003.
Metformin: The Cornerstone of Diabetes Treatment
- Metformin is identified as the most effective and widely used medication for Type 2 diabetes; its low cost makes it less favored by pharmaceutical companies.
- It targets fasting hyperglycemia caused by uncontrolled hepatic gluconeogenesis, making it essential in managing Type 2 diabetes (90%-95% of cases).
Mechanism and Effects of Metformin
- Metformin primarily reduces hepatic gluconeogenesis but also has secondary effects such as decreasing intestinal glucose absorption and slightly increasing insulin sensitivity.
- Gastrointestinal discomfort is noted as a common side effect (up to 30% incidence), including symptoms like bloating, nausea, vomiting, and diarrhea.
Safety and Dosage Considerations
- Cautions against using metformin in patients with renal impairment or metabolic acidosis due to risks like lactic acidosis; monitoring B12 levels is recommended due to potential deficiency.
- The ideal dosage for metformin is discussed: starting at 500 mg initially for tolerance assessment before increasing to a maximum effective dose of 2 g per day.
Sulfonylureas: An Alternative Approach
Characteristics of Sulfonylureas
- Sulfonylureas are highlighted as powerful alternatives that can lower HbA1c levels significantly but do not reduce cardiovascular risk compared to metformin.
Usage Recommendations
- Recommended for use within the first five years post-diagnosis; caution advised for patients with existing cardiovascular conditions due to associated risks.
Mechanism of Action
Insulin Secretion and Sensitivity in Diabetes Management
Mechanisms of Insulin Secretion
- The primary effect of certain medications is to increase insulin secretion, which enhances the body's ability to manage blood sugar levels.
- These medications also improve peripheral insulin sensitivity, a significant benefit that surpasses the effects of metformin.
Ideal Candidates for Sulfonylureas
- Sulfonylureas are particularly suitable for non-obese Type 2 diabetics, as they can lead to weight gain; about 20% of Type 2 diabetics fall into this category.
- Caution is advised when prescribing sulfonylureas to patients with cardiovascular disease or renal impairment (eGFR < 30), as these conditions contraindicate their use.
Adverse Effects and Usage Guidelines
- The main adverse effect associated with sulfonylureas is moderate hypoglycemia, which is more pronounced than with metformin but not severe.
- Commonly used sulfonylurea includes glibenclamide, typically dosed from 5 mg up to 30 mg, taken 30 minutes before meals.
Thiazolidinediones and Their Role
Benefits and Limitations
- Thiazolidinediones like pioglitazone enhance insulin response in peripheral tissues but have limited use due to potential heart failure risks.
- They may cause edema and should be avoided in patients with any degree of heart failure.
Meglitinides: A Rapid Action Alternative
Mechanism and Application
- Meglitinides function similarly to sulfonylureas by increasing insulin secretion but do so through different mechanisms involving calcium channel blockade.
- They are particularly effective for managing severe postprandial hyperglycemia due to their rapid action profile akin to ultra-fast insulins like lispro.
Modern Diabetes Treatments: SGLT2 Inhibitors
Preventive Properties
- SGLT2 inhibitors are considered highly effective not just for controlling diabetes but also for preventing vascular complications associated with the disease.
Understanding the Role of Gliflocinas in Diabetes Management
Mechanism and Benefits of Gliflocinas
- The kidneys continuously absorb glucose, which can lead to increased blood sugar levels. Japanese researchers discovered that a selective inhibitor of this co-transporter results in glucosuria, reducing glucose reabsorption.
- Glucosuria is highlighted as a significant outcome, providing protection against complications related to diabetes, particularly cardiac issues and slowing the progression of atherosclerosis.
- Gliflocinas are beneficial even for patients without diabetes due to their diuretic effects and utility in managing heart failure with preserved or reduced ejection fraction.
- These medications have shown proven efficacy in delaying renal disease progression, especially when microalbuminuria is detected early on.
- Treatment recommendations for diabetic patients depend on comorbidities; metformin remains the first-line treatment unless other conditions necessitate alternative therapies.
Cost and Side Effects
- The average monthly cost for gliflocinas is around 200-250 soles, significantly lower than GLP1 agonists which can range from 5 to 15 times that amount.
- Common side effects include fungal infections (especially candidiasis), urinary tract infections due to glucosuria, and an increased risk of diabetic ketoacidosis in susceptible patients.
Inhibitors of Dipeptidyl Peptidase IV (DPP-IV)
Functionality and Usage
- DPP-IV inhibitors enhance incretin activity by preventing the breakdown of GLP1 and GIP. Examples include sitagliptin and linagliptin, which are widely promoted by pharmaceutical companies.
- These drugs increase incretin activity indirectly but have limited potency compared to gliflocinas; they typically reduce HbA1c by about 0.5%.
Safety Profile
- DPP-IV inhibitors are generally safe for use in advanced renal disease; linagliptin does not require dose adjustment based on kidney function.
- Caution is advised against combining these medications with insulin due to a heightened risk of hypoglycemia.
GLP1 Receptor Agonists: Current Trends
Overview and Efficacy
Overview of GLP-1 Agonists and Their Role in Obesity Management
Introduction to GLP-1 Agonists
- The discussion begins with a mention of short-acting and long-acting GLP-1 agonists, including albiglutide (long-acting) and tirzepatide (the only dual-action drug currently available).
Key Medications in Focus
- Semaglutide is highlighted as a popular choice for weight loss management, although it is not yet widely available in the country.
Mechanism of Action
Incretin Mimetics
- These drugs mimic incretin hormones released during food intake, which stimulate insulin secretion and help regulate blood sugar levels.
Effects on Gastric Emptying and Glucagon Secretion
- They slow gastric emptying, promoting satiety, while also decreasing glucagon secretion—important for preventing hypoglycemia.
Benefits in Weight Management
Satiety Induction
- Patients using these medications report prolonged feelings of fullness, leading to reduced food intake.
Weight Loss Outcomes
- Notable weight loss results are reported: an average of 10 kg lost within 8 weeks; some patients have lost up to 20 kg.
Cardiovascular and Renal Implications
Additional Health Benefits
- These medications may lower cardiovascular risk similarly to SGLT2 inhibitors and can slightly delay chronic kidney disease progression.
Adverse Effects and Contraindications
Common Side Effects
- Potential side effects include nausea, vomiting, diarrhea, injection site reactions, and a rare risk of autoimmune pancreatitis.
Specific Contraindications
- Caution is advised for patients with a history of medullary thyroid carcinoma due to increased tumor risk associated with these drugs.
Alternative Treatments: Pramlintide
Unique Mechanism
- Pramlintide acts as a synthetic analog of amylin that inhibits glucagon secretion while also delaying gastric emptying.
Application in Diabetes Management
- It can be used effectively in both Type 1 and Type 2 diabetes patients alongside insulin therapy.
Conclusion on Treatment Efficacy
Importance in Pediatric Obesity